Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Dotinurad

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Revarazan Hcl For Acute Gastritis, Chronic Gastritis Gastric Mucosal Lesions
    Revarazan Hcl For Acute Gastritis, Chronic Gastritis Gastric Mucosal Lesions

    28 Mar 2024

    // PRESS RELEASE

    https://www.tantuchemicals.com/news/revarazan-hcl-for-acute-gastritis-chronic-gas-76202020.html

    PRESS RELEASE
    28 Mar 2024
    Share Share
    Urica Announces Topline Data from the Ph1 Trial Evaluating Dotinurad
    Urica Announces Topline Data from the Ph1 Trial Evaluating Dotinurad

    29 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/29/2696949/28889/en/Urica-Therapeutics-Announces-Topline-Data-from-the-Phase-1-Clinical-Trial-Evaluating-Dotinurad-in-Healthy-Volunteers-in-the-United-States.html

    GLOBENEWSWIRE
    29 Jun 2023
    Share Share
    Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin
    Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin

    14 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/14/2573643/28889/en/Urica-Therapeutics-Expands-Exclusive-License-Agreement-with-Fuji-Yakuhin-Co-Ltd-to-Develop-Dotinurad-in-Additional-Territories-Including-Turkey-and-the-Middle-East-and-North-Africa.html

    GLOBENEWSWIRE
    14 Dec 2022
    Share Share
    Fortress Biotech Announces First Patient Dosed in PI Trial of Dotinurad
    Fortress Biotech Announces First Patient Dosed in PI Trial of Dotinurad

    31 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/31/2453275/28889/en/Fortress-Biotech-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-Evaluating-Dotinurad-for-the-Treatment-of-Gout-in-the-United-States.html

    GLOBENEWSWIRE
    31 May 2022
    Share Share